Furthermore, given the consistency of the OUtMATCH results with previous studies, the Expert Group concluded that there is now sufficient evidence to recommend omalizumab as monotherapy for use in selected patients with IgE‐mediated food allergy (Figure 1A). This evidence concerns the gene IGHE and food allergy.